Veracyte, Inc. (VCYT) Stock Analysis and Metrics

Veracyte

NASDAQ: VCYT

$57.48 ▲ +0.51 (+0.90%)

At close: Jul 13, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap4.76 Bn

P/E54.09

P/S8.79

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)982,000.00

Revenue Growth (1y) (Qtr)21.49

Add ratio to table…

About

Veracyte Inc is a global diagnostics company that develops and commercializes molecular diagnostic tests to guide cancer care. The company’s portfolio includes tests for thyroid, prostate, bladder, breast and lung cancer that help clinicians personalize treatment avoid unnecessary procedures and improve patient outcomes. Veracyte serves patients worldwide through two complementary models: laboratory developed tests performed in its CLIA certified labs in the United States and in vitro diagnostic kits sold to hospitals and laboratories outside the United States. Veracyte aims to progress patient care from a standard approach to a more individualized strategy by leveraging each patient’s unique cancer biology. As of December 31 2025 the company employed 755 people and operated CLIA certified laboratories in South San Francisco, San Diego, and Austin.

Veracyte generates revenue primarily from sales of its laboratory developed tests performed in its CLIA certified laboratories in the United States and from the sale of in vitro diagnostic test kits to hospitals and laboratories outside the United States. The company also earns revenue from collaborations with biopharmaceutical partners that use data from its clinical tests to support drug development. In 2025 the majority of Veracyte’s revenue came from the Decipher Prostate and Afirma tests which together accounted for most of its testing revenue. According to its payer mix Medicare Fee For Service represented 34%, Medicare Advantage 18%, Medicaid 1%, and private commercial payers 47% of testing revenue. Biopharmaceutical and other revenue arises from partnerships that utilize data from Veracyte’s CLIA tests to provide insights into disease genetics.

The company operates through the following segments.

• United States Clinical Diagnostics: This segment provides laboratory developed tests such as Afirma for thyroid cancer, Decipher Prostate for prostate cancer, Decipher Bladder for bladder cancer, and Prosigna for breast cancer through Veracyte’s CLIA certified labs in South San Francisco, San Diego, and Austin.

• International In Vitro Diagnostic: This segment offers in vitro diagnostic versions of its tests including Prosigna and soon Decipher Prostate to hospitals and laboratories outside the United States where the tests are performed locally on platforms such as the nCounter Analysis System and the NextSeq 550Dx, and it generates revenue from sales of Prosigna IVD kits in Europe, the Middle East, Asia Pacific, and Latin America and from collaborations with Illumina to develop decentralized IVD tests on the NextSeq 550Dx platform.

Veracyte competes with companies such as Myriad Genetics, MDxHealth, Interpace Diagnostics, ThyroSeq, Natera, Guardant Health, Exact Sciences, and TempusAI in the cancer diagnostics market. The company’s competitive advantages stem from its Veracyte Diagnostics Platform which combines whole transcriptome data, bioinformatics, artificial intelligence, and a strong evidence generation engine to support reimbursement guideline adoption and continuous innovation. Veracyte’s strong relationships with key opinion leaders, broad publication record, and established payer coverage policies create barriers to entry and help sustain its market position.

Veracyte serves physicians, hospitals, and clinical laboratories that order its tests for patients suspected of having cancer. Its customers include endocrinologists, urologists, oncologists, and pathologists who use the Afirma Decipher Prostate, Decipher Bladder, and Prosigna assays to inform diagnosis prognosis and treatment decisions. The company also works with biopharmaceutical firms, public payers, and private payers that provide reimbursement for its tests and license its diagnostic data for drug development.

Investment Thesis

▲ Bull case

Veracyte is positioned for accelerated growth driven by the imminent commercial launches of Prosigna LDT and TruMRD, which represent transformative opportunities beyond its core franchises. Prosigna LDT, with its LDT version enabling faster reimbursement and broader access than the kit-based version, targets the large addressable market of approximately 225,000 annual early-stage HR+/HER2- breast cancer patients in the U.S., and the OPTIMA trial results demonstrating that more than two-thirds of high-risk patients can safely avoid chemotherapy provide Level 1A evidence that could rapidly drive adoption and guideline inclusion. TruMRD, having secured CMS MolDX coverage for muscle-invasive bladder cancer (MIBC) effective June 1, 2026, addresses a significant unmet need in recurrence monitoring for the ~21,250 MIBC patients annually (25% of 85,000 bladder cancer cases), with clinical evidence showing it detects recurrence a median of 131 days earlier than imaging, creating a strong value proposition for urologists and oncologists. The company’s established commercial channels in urology and radiation oncology, where 70% of MIBC patients are seen, provide a ready-made pathway for TruMRD adoption, while Prosigna leverages existing breast cancer relationships and the growing demand for precision oncology to avoid overtreatment. These launches are not incremental but represent platform extensions into new high-growth markets, with management indicating they will be scaled based on early traction, reducing near-term execution risk while preserving long-term upside.
The core franchises of Decipher and Afirma exhibit sustainable, multi-year growth trajectories underpinned by deep clinical evidence moats and significant headroom for penetration, which the market may be underappreciating due to near-term focus on new product risks. Decipher, with only one in three U.S. prostate cancer patients currently benefiting from the test, has a vast addressable market supported by over a decade of NCCN guideline inclusion and evolving evidence from trials like ENZAMET (showing benefit in metastatic disease guiding triplet therapy) and GUIDANCE (evaluating treatment de-intensification in unfavorable intermediate-risk cancer), which together expand its utility across the entire prostate cancer continuum from active surveillance to metastatic disease. This is evidenced by nearly 30% year-over-year growth in high-risk categories in Q1 FY26, signaling successful expansion beyond initial use cases. Afirma’s growth is being driven by operational improvements from the V2 transcriptome workflow, which reduced no-result rates and contributed approximately 400 basis points to volume growth in Q1 FY26, with management noting this benefit is sustainable through seasonal adjustments (2-3% annual guidance) and not reliant on one-time prior period collections. The franchise benefits from real-world impact data showing reduced thyroid surgery rates among Medicare beneficiaries, reinforcing its value proposition to payers and providers, and its expanding Afirma GRID database continues to generate new molecular signatures that enhance clinical utility without requiring new test development. Both franchises benefit from pricing upside potential, with Decipher showing stronger normalized ASP trends (up 3% ex-PPC) and Afirma having room for gradual increases given its 280 million covered lives, suggesting the current guidance of high single-digit to low double-digit revenue growth for Afirma and ~20% for Decipher is conservative.
Veracyte’s financial profile reflects operating leverage and capital efficiency that could support aggressive reinvestment or shareholder returns, with the market potentially overlooking the scalability of its model as it transitions from investment phase to cash flow generation. The company generated $35.2 million in operating cash flow in Q1 FY26, ending the quarter with $439.1 million in cash, cash equivalents, and short-term investments, providing a substantial war chest for funding launches, M&A, or share repurchases without diluting shareholders. Adjusted EBITDA margin reached 30.8% in Q1 FY26, exceeding the 25% long-term target and prompting an upward revision of full-year guidance to greater than 26% of revenue, driven by 75.7% non-GAAP gross margin (up 350 basis points year-over-year) from improved business mix and operational efficiencies in the V2 transcriptome workflow. This margin expansion is structural, not temporary, as it stems from scalable lab processes and a shift toward higher-margin testing revenue (which grew 26% year-over-year to $135.1 million), while non-GAAP operating expenses grew only 7% year-over-year to $64.6 million despite significant R&D investment ($24.1 million, up $8.5 million) for pipeline advancement. The company’s ability to maintain double-digit revenue and volume growth (21% and 17% year-over-year, respectively) while expanding margins indicates strong operating leverage, and with guidance excluding new product contributions, any upside from Prosigna LDT and TruMRD would flow directly to the bottom line, potentially enabling accelerated adjusted EBITDA margin expansion beyond current expectations if launches gain traction faster than anticipated.

Veracyte is positioned for accelerated growth driven by the imminent commercial launches of Prosigna LDT and TruMRD, which represent transformative opportunities beyond its core franchises. Prosigna LDT, with its LDT version enabling faster reimbursement and broader access than the kit-based version, targets the large addressable market of approximately 225,000 annual early-stage HR+/HER2- breast cancer patients in the U.S., and the OPTIMA trial results demonstrating that more than two-thirds of high-risk patients can safely avoid chemotherapy provide Level 1A evidence that could rapidly drive adoption and guideline inclusion. TruMRD, having secured CMS MolDX coverage for muscle-invasive bladder cancer (MIBC) effective June 1, 2026, addresses a significant unmet need in recurrence monitoring for the ~21,250 MIBC patients annually (25% of 85,000 bladder cancer cases), with clinical evidence showing it detects recurrence a median of 131 days earlier than imaging, creating a strong value proposition for urologists and oncologists. The company’s established commercial channels in urology and radiation oncology, where 70% of MIBC patients are seen, provide a ready-made pathway for TruMRD adoption, while Prosigna leverages existing breast cancer relationships and the growing demand for precision oncology to avoid overtreatment. These launches are not incremental but represent platform extensions into new high-growth markets, with management indicating they will be scaled based on early traction, reducing near-term execution risk while preserving long-term upside.
The core franchises of Decipher and Afirma exhibit sustainable, multi-year growth trajectories underpinned by deep clinical evidence moats and significant headroom for penetration, which the market may be underappreciating due to near-term focus on new product risks. Decipher, with only one in three U.S. prostate cancer patients currently benefiting from the test, has a vast addressable market supported by over a decade of NCCN guideline inclusion and evolving evidence from trials like ENZAMET (showing benefit in metastatic disease guiding triplet therapy) and GUIDANCE (evaluating treatment de-intensification in unfavorable intermediate-risk cancer), which together expand its utility across the entire prostate cancer continuum from active surveillance to metastatic disease. This is evidenced by nearly 30% year-over-year growth in high-risk categories in Q1 FY26, signaling successful expansion beyond initial use cases. Afirma’s growth is being driven by operational improvements from the V2 transcriptome workflow, which reduced no-result rates and contributed approximately 400 basis points to volume growth in Q1 FY26, with management noting this benefit is sustainable through seasonal adjustments (2-3% annual guidance) and not reliant on one-time prior period collections. The franchise benefits from real-world impact data showing reduced thyroid surgery rates among Medicare beneficiaries, reinforcing its value proposition to payers and providers, and its expanding Afirma GRID database continues to generate new molecular signatures that enhance clinical utility without requiring new test development. Both franchises benefit from pricing upside potential, with Decipher showing stronger normalized ASP trends (up 3% ex-PPC) and Afirma having room for gradual increases given its 280 million covered lives, suggesting the current guidance of high single-digit to low double-digit revenue growth for Afirma and ~20% for Decipher is conservative.
Veracyte’s financial profile reflects operating leverage and capital efficiency that could support aggressive reinvestment or shareholder returns, with the market potentially overlooking the scalability of its model as it transitions from investment phase to cash flow generation. The company generated $35.2 million in operating cash flow in Q1 FY26, ending the quarter with $439.1 million in cash, cash equivalents, and short-term investments, providing a substantial war chest for funding launches, M&A, or share repurchases without diluting shareholders. Adjusted EBITDA margin reached 30.8% in Q1 FY26, exceeding the 25% long-term target and prompting an upward revision of full-year guidance to greater than 26% of revenue, driven by 75.7% non-GAAP gross margin (up 350 basis points year-over-year) from improved business mix and operational efficiencies in the V2 transcriptome workflow. This margin expansion is structural, not temporary, as it stems from scalable lab processes and a shift toward higher-margin testing revenue (which grew 26% year-over-year to $135.1 million), while non-GAAP operating expenses grew only 7% year-over-year to $64.6 million despite significant R&D investment ($24.1 million, up $8.5 million) for pipeline advancement. The company’s ability to maintain double-digit revenue and volume growth (21% and 17% year-over-year, respectively) while expanding margins indicates strong operating leverage, and with guidance excluding new product contributions, any upside from Prosigna LDT and TruMRD would flow directly to the bottom line, potentially enabling accelerated adjusted EBITDA margin expansion beyond current expectations if launches gain traction faster than anticipated.

▼ Bear case

Veracyte faces significant near-term execution risks in launching Prosigna LDT and TruMRD that the market may be underestimating, particularly regarding reimbursement, clinical adoption, and competitive pressures, despite positive early signals. While TruMRD secured CMS MolDX coverage for MIBC recurrence monitoring effective June 1, 2026, this coverage is limited to a specific indication and may not guarantee broad payer adoption, as commercial payers often lag Medicare in covering new molecular diagnostics, and the company must still establish clinical utility beyond imaging to drive utilization—current evidence from the PAGER study shows earlier detection but not yet improved survival outcomes, which payers increasingly require for coverage decisions. Prosigna LDT’s success hinges on the OPTIMA trial’s primary endpoint readout, which management acknowledged has a “quite high bar” requiring noninferiority on the predictive claim for Level 1A evidence; if the results are ambiguous or negative, guideline inclusion by NCCN (targeted for August 2026 review) becomes uncertain, potentially limiting adoption to discretionary use rather than standard of care, and the test faces entrenched competition from Oncotype DX, which is already guideline-recommended and has lower nodal restrictions (approved for up to three nodes vs. OPTIMA’s up to nine nodes), creating a reimbursement and perception hurdle. Additionally, the launch timing—Prosigna LDT available to order June 8, 2026, and TruMRD launching in MIBC by end of Q2 FY26—coincides with historical seasonal softness in testing volumes (noted by management as no-result rate spikes in summer months due to RNA degradation), which could blunt initial uptake and create volatility in early quarterly results that the market may misinterpret as weakness.
The core Decipher franchise, while currently growing, risks deceleration due to market saturation in its established use cases and emerging threats from lower-cost digital pathology and AI-based competitors that could erode its competitive moat over time, a dynamic management acknowledged but did not fully address in terms of timelines or countermeasures. Although management cited Decipher’s “competitive moat” from over a decade of evidence and NCCN inclusion, they conceded that digital pathology/AI launches are recent and face skepticism due to discordant results, but did not detail how Veracyte will defend against cost-driven adoption shifts—particularly as healthcare systems increasingly prioritize cost containment, and emerging competitors may offer similar prognostic information at lower price points through AI-enhanced histopathology. The franchise’s growth is heavily dependent on expanding into new indications like high-risk and metastatic disease (where it saw nearly 30% year-over-year growth in Q1 FY26), but these segments are smaller and more complex to serve, requiring longer sales cycles and greater clinical education, which may limit scalability. Furthermore, Decipher’s reliance on tissue-based testing makes it vulnerable to shifts toward liquid biopsy technologies (e.g., ctDNA for prostate cancer), which are less invasive and gaining traction in monitoring, and while Veracyte is exploring complementary digital pathology initiatives, it has not yet integrated such technologies into its core test, potentially leaving it behind if the market shifts decisively toward non-invasive or imaging-adjacent solutions.
Veracyte’s financial guidance and capital allocation strategy may conceal underlying vulnerabilities, particularly around the sustainability of margin expansion and the reliance on non-recurring benefits that could flatter current profitability, despite management’s transparency about certain adjustments. While the company emphasized that prior period collections (PPCs) contributed a $4 million one-time benefit to Q1 FY26 ASP and are excluded from forward guidance, the normalized ASP increase of only 3% year-over-year (ex-PPC) suggests limited pricing power in the core franchises, and Afirma’s ex-PParam ASP rose just 100 basis points, indicating minimal room for ASP growth in the thyroid franchise despite its 280 million covered lives—this contrasts with management’s optimism about Decipher’s ASP upside and raises questions about whether the current gross margin expansion (non-GAAP gross margin up 350 basis points to 75.7%) is truly sustainable or partly driven by temporary operational efficiencies that may normalize as new product launches increase cost structure. The significant increase in R&D expenses ($24.1 million, up $8.5 million year-over-year) reflects investment in pipeline advancement, but with over 10 studies in testing/analysis, 12 in contracting, and 29 in planning, the company is spreading resources across multiple indications (bladder, breast, lung, colorectal, prostate, kidney, immunotherapy), which could dilute focus and delay meaningful readouts, increasing the risk that pipeline investments fail to translate into near-term revenue contributors. Additionally, while the $439.1 million cash balance provides flexibility, the company’s history of avoiding M&A and preference for organic growth may limit its ability to respond to competitive threats or accelerate market share gains in new areas like MRD, where larger diagnostics players could leverage scale and established relationships to challenge TruMRD’s entry.

Veracyte faces significant near-term execution risks in launching Prosigna LDT and TruMRD that the market may be underestimating, particularly regarding reimbursement, clinical adoption, and competitive pressures, despite positive early signals. While TruMRD secured CMS MolDX coverage for MIBC recurrence monitoring effective June 1, 2026, this coverage is limited to a specific indication and may not guarantee broad payer adoption, as commercial payers often lag Medicare in covering new molecular diagnostics, and the company must still establish clinical utility beyond imaging to drive utilization—current evidence from the PAGER study shows earlier detection but not yet improved survival outcomes, which payers increasingly require for coverage decisions. Prosigna LDT’s success hinges on the OPTIMA trial’s primary endpoint readout, which management acknowledged has a “quite high bar” requiring noninferiority on the predictive claim for Level 1A evidence; if the results are ambiguous or negative, guideline inclusion by NCCN (targeted for August 2026 review) becomes uncertain, potentially limiting adoption to discretionary use rather than standard of care, and the test faces entrenched competition from Oncotype DX, which is already guideline-recommended and has lower nodal restrictions (approved for up to three nodes vs. OPTIMA’s up to nine nodes), creating a reimbursement and perception hurdle. Additionally, the launch timing—Prosigna LDT available to order June 8, 2026, and TruMRD launching in MIBC by end of Q2 FY26—coincides with historical seasonal softness in testing volumes (noted by management as no-result rate spikes in summer months due to RNA degradation), which could blunt initial uptake and create volatility in early quarterly results that the market may misinterpret as weakness.
The core Decipher franchise, while currently growing, risks deceleration due to market saturation in its established use cases and emerging threats from lower-cost digital pathology and AI-based competitors that could erode its competitive moat over time, a dynamic management acknowledged but did not fully address in terms of timelines or countermeasures. Although management cited Decipher’s “competitive moat” from over a decade of evidence and NCCN inclusion, they conceded that digital pathology/AI launches are recent and face skepticism due to discordant results, but did not detail how Veracyte will defend against cost-driven adoption shifts—particularly as healthcare systems increasingly prioritize cost containment, and emerging competitors may offer similar prognostic information at lower price points through AI-enhanced histopathology. The franchise’s growth is heavily dependent on expanding into new indications like high-risk and metastatic disease (where it saw nearly 30% year-over-year growth in Q1 FY26), but these segments are smaller and more complex to serve, requiring longer sales cycles and greater clinical education, which may limit scalability. Furthermore, Decipher’s reliance on tissue-based testing makes it vulnerable to shifts toward liquid biopsy technologies (e.g., ctDNA for prostate cancer), which are less invasive and gaining traction in monitoring, and while Veracyte is exploring complementary digital pathology initiatives, it has not yet integrated such technologies into its core test, potentially leaving it behind if the market shifts decisively toward non-invasive or imaging-adjacent solutions.
Veracyte’s financial guidance and capital allocation strategy may conceal underlying vulnerabilities, particularly around the sustainability of margin expansion and the reliance on non-recurring benefits that could flatter current profitability, despite management’s transparency about certain adjustments. While the company emphasized that prior period collections (PPCs) contributed a $4 million one-time benefit to Q1 FY26 ASP and are excluded from forward guidance, the normalized ASP increase of only 3% year-over-year (ex-PPC) suggests limited pricing power in the core franchises, and Afirma’s ex-PParam ASP rose just 100 basis points, indicating minimal room for ASP growth in the thyroid franchise despite its 280 million covered lives—this contrasts with management’s optimism about Decipher’s ASP upside and raises questions about whether the current gross margin expansion (non-GAAP gross margin up 350 basis points to 75.7%) is truly sustainable or partly driven by temporary operational efficiencies that may normalize as new product launches increase cost structure. The significant increase in R&D expenses ($24.1 million, up $8.5 million year-over-year) reflects investment in pipeline advancement, but with over 10 studies in testing/analysis, 12 in contracting, and 29 in planning, the company is spreading resources across multiple indications (bladder, breast, lung, colorectal, prostate, kidney, immunotherapy), which could dilute focus and delay meaningful readouts, increasing the risk that pipeline investments fail to translate into near-term revenue contributors. Additionally, while the $439.1 million cash balance provides flexibility, the company’s history of avoiding M&A and preference for organic growth may limit its ability to respond to competitive threats or accelerate market share gains in new areas like MRD, where larger diagnostics players could leverage scale and established relationships to challenge TruMRD’s entry.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password